Zymeworks Appoints Computational Antibody Design Expert Dr. Bruce Tidor to its Scientific Advisory Board

Zymeworks Appoints Computational Antibody Design Expert Dr. Bruce Tidor to its Scientific Advisory Board

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc., a privately held computational biotechnology company, today announced the appointment of Dr. Bruce Tidor, Professor in the Departments of Biological Engineering and of Electrical Engineering and Computer Science at the Massachusetts Institute of Technology (MIT), to its scientific advisory board.

"Dr. Tidor is renowned in academia and industry for his use of leading-edge computational methodologies to understand and engineer protein therapeutics," says Dr. Ali Tehrani, President and CEO of Zymeworks. "His unique cross-disciplinary blend of expertise and vision in modeling and biochemistry will be invaluable to Zymeworks' ongoing technology refinement in rational protein optimization and engineering."

Dr. Bruce Tidor is Professor of Biological Engineering and Computer Science and is a member of the Computer Science and Artificial Intelligence Laboratory at MIT. With over 100 peer-reviewed publications, Dr. Tidor's prolific research centers on the use of molecular modeling and computation to understand protein and nucleic acid structures, functions, and interactions. One of his recent highly regarded studies described the use of rational design to optimize monoclonal antibodies Avastin® and Erbitux®, leading to the opportunity to use similar approaches to develop second-generation protein therapeutics. Dr. Tidor graduated summa cum laude with an A.B. in Chemistry and Physics from Harvard College, earned a M.Sc. in Biochemistry at Oxford University's Wolfson College as a Marshall Scholar, and received his Ph.D. in Biophysics from Harvard. He was a Whitehead Fellow at the Whitehead Institute for Biomedical Research and currently serves as the founding co-Director of MIT's Computational and Systems Biology Initiative.

About Zymeworks Inc.

Zymeworks is a computational biotechnology company researching and developing next-generation protein therapeutics. Zymeworks leverages proprietary insight into structure-function relationships generated by the ZymeCADTM platform to optimize the efficacy and potency of protein therapeutics. Zymeworks is focused on developing a biotherapeutics pipeline through strategic collaborations and internal research programs. More information on Zymeworks can be found at http://www.zymeworks.com.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.